ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BACKGROUND: Hypoxia inducible factor 2-alpha (HIF2a) is a stress response transcription factor that mediates the cellular response to hypoxia. HIF2a is an underexplored target in glioma. PT2385 is a first-in-class oral HIF2a inhibitor with favorable blood-brain barrier penetrating properties and in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Strowd, Roy, Ellingson, Benjamin, Wen, Patrick, Ahluwalia, Manmeet, Piotrowski, Anna, Desai, Arati, Clarke, Jennifer, Lieberman, Frank, Desideri, Serena, Nabors, L Burt, Grossman, Stuart
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216170/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.049
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki